维普中文期刊产品整合服务
66篇 您的检索式:作者名="Sconce"
    题名 作者 年代 出处 被引量
1The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen 显示文摘SCONCE E A KHAN T I WYNNE H A 2005Blood2005,106,7:1
2The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen显示文摘Sconce EA Khan TI Wynne HA 2005Blood2005,106,7:1
3APOE genotype makes a small contribution to warfarin dose requirements显示文摘Sconce EA Daly AK Khan TI 2006Pharmacogenet Genomics2006,16,8:1
4The impact of CYP2C9 and VKORC1 genetic polymorphlsm and patient charac- teristics upon warfarin dose requirements:proposal for a new do- sing regimen 显示文摘SCONCE E A KHAN T I WYNNE H A 2005Blood2005,106,7:1
5The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen显示文摘Sconce EA Khan TI Wynne HA 2005Blood2005,106,7:1
6The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen显示文摘Sconce EA Khan IT King BP 2005Blood2005,106,7:1
7The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon war- farin dose requirements: proposal for a new dosing regimen 显示文摘Sconce EA Khan TI Wynne HA 2005Blood2005,106,7:1
8APOE genotype makes a small contribution to warfarin dose requirements显示文摘Sconce EA Daly AK Khan TI 2006Pharmacogenet Ge- nomics2006,16,8:1
9The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen显示文摘Sconce EA Khan TI Wynne HA 2005Blood2005,106,7:1
10The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen显示文摘Sconce EA Khan TI Wynne HA 2005Blood2005,106,7:1
11The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen 显示文摘SCONCE EA KHAN TI WYNNE HA 2005Blood2005,106,7:1
12The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen显示文摘Sconce EA Khan TI Wynne HA 2005Blood2005,106,7:1
13The im- pact of CYP2C9 and VKORC1 genetic polymor- phism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regi men显示文摘Sconce EA Khan TI Wynne HA 2005Blood2005,106,7:1
14The impact of CYP2C9 and VKORC1 genetic poly-morphism and patient characteristics upon warfarin dose requireme, nts: proposal for a new dosing regimen显示文摘Sconce EA Khan TI Wynne HA 2005Blood2005,106,:1
15The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen显示文摘SCONCE E A KHAN T I WYNNE H A 2005Blood2005,106,7:1
16The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon war- farin dose requirements:proposal for a new dosing regimen显示文摘Sconce EA Khan TI Wynne HA 2005Blood2005,106,7:1
17The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen显示文摘Sconce EA Khan TI Wynne HA Avery P Monkhouse L King BP 2005Blood2005,106,:1
18APOE genotype makes a small contribution to warfarin dose requirements 显示文摘Sconce E A Daly A K Khan T I 2006Pharmacogenet Genomics2006,16,8:1
19The impact of CYP2C9 and VKORC1 genetic poly-morphism and patient characteristics upon warfarin dose requirements:proposal for a new dosing regimen显示文摘Sconce EA Khan TI Wynne HA 2005Blood2005,106,7:1
20The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristic upon warfarin dose requirements : proposal for a new dosing regimen 显示文摘Sconce EA Khan TI Wynne HA 2005Blood2005,106,:1
返回顶部 每页显示:
共4页 首页 上一页 第1页 下一页 末页 /4 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费